Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 336

1.

Characteristics of footwear worn by people with systemic lupus erythematosus: a comparison with age- and sex-matched healthy controls: a pilot study.

Stewart S, Keys M, Brenton-Rule A, Aiyer A, Dalbeth N, Rome K.

J Foot Ankle Res. 2018 Jul 5;11:38. doi: 10.1186/s13047-018-0280-3. eCollection 2018.

2.

Mediation analysis to understand genetic relationships between habitual coffee intake and gout.

Hutton J, Fatima T, Major TJ, Topless R, Stamp LK, Merriman TR, Dalbeth N.

Arthritis Res Ther. 2018 Jul 5;20(1):135. doi: 10.1186/s13075-018-1629-5.

3.

Keeping Up with the Applications: Lessons Learned Evaluating Gout Apps.

Kieser A, Dalbeth N, Serlachius A.

Telemed J E Health. 2018 Jul 3. doi: 10.1089/tmj.2018.0091. [Epub ahead of print]

PMID:
29969385
4.

Association of Crohn's disease-related chromosome 1q32 with ankylosing spondylitis is independent of bowel symptoms and faecal calprotectin.

Roberts RL, Wallace MC, Harrison AA, White D, Dalbeth N, Stamp LK, Ching D, Highton J, Merriman TR, Robinson PC, Brown MA, Stebbings SM.

PeerJ. 2018 Jun 26;6:e5088. doi: 10.7717/peerj.5088. eCollection 2018.

5.

Implications of the cardiovascular safety of febuxostat and allopurinol in patients with gout and cardiovascular morbidities (CARES) trial and associated FDA public safety alert.

Choi H, Neogi T, Stamp L, Dalbeth N, Terkeltaub R.

Arthritis Rheumatol. 2018 Jun 5. doi: 10.1002/art.40583. [Epub ahead of print] Review.

PMID:
29869840
6.

Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN) consensus statement regarding labels and definitions for disease elements in gout.

Bursill D, Taylor WJ, Terkeltaub R, Kuwabara M, Merriman TR, Grainger R, Pineda C, Louthrenoo W, Edwards NL, Andrés M, Vargas-Santos AB, Roddy E, Pascart T, Lin CT, Perez-Ruiz F, Tedeschi SK, Kim SC, Harrold LR, McCarthy G, Kumar N, Chapman PT, Tausche AK, Vazquez-Mellado J, Gutierrez M, Pinheiro GDRC, Richette P, Pascual E, Fisher MC, Burgos-Vargas R, Robinson PC, Singh JA, Jansen TL, Saag KG, Slot O, Uhlig T, Solomon DH, Keenan RT, Scire CA, Biernat-Kaluza E, Dehlin M, Nuki G, Schlesinger N, Janssen M, Stamp LK, Sivera F, Reginato AM, Jacobsson L, Lioté F, Ea HK, Rosenthal A, Bardin T, Choi HK, Hershfield MS, Czegley C, Choi SJ, Dalbeth N.

Arthritis Care Res (Hoboken). 2018 May 25. doi: 10.1002/acr.23607. [Epub ahead of print]

PMID:
29799677
7.

'Googling' Gout: Exploring perceptions about gout through a linguistic analysis of online search activities.

Jordan KN, Pennebaker JW, Petrie KJ, Dalbeth N.

Arthritis Care Res (Hoboken). 2018 May 21. doi: 10.1002/acr.23598. [Epub ahead of print]

PMID:
29781577
8.

An update on the genetics of hyperuricaemia and gout.

Major TJ, Dalbeth N, Stahl EA, Merriman TR.

Nat Rev Rheumatol. 2018 Jun;14(6):341-353. doi: 10.1038/s41584-018-0004-x. Review.

PMID:
29740155
9.

Ankle joint function during walking in tophaceous gout: A biomechanical gait analysis study.

Carroll M, Boocock M, Dalbeth N, Stewart S, Frampton C, Rome K.

Gait Posture. 2018 Jun;63:150-153. doi: 10.1016/j.gaitpost.2018.04.020. Epub 2018 Apr 17.

PMID:
29734124
10.

Discordant association of the CREBRF rs373863828 A allele with increased BMI and protection from type 2 diabetes in Māori and Pacific (Polynesian) people living in Aotearoa/New Zealand.

Krishnan M, Major TJ, Topless RK, Dewes O, Yu L, Thompson JMD, McCowan L, de Zoysa J, Stamp LK, Dalbeth N, Harré Hindmarsh J, Rapana N, Deka R, Eng WWH, Weeks DE, Minster RL, McGarvey ST, Viali S, Naseri T, Sefuiva Reupena M, Wilcox P, Grattan D, Shepherd PR, Shelling AN, Murphy R, Merriman TR.

Diabetologia. 2018 Jul;61(7):1603-1613. doi: 10.1007/s00125-018-4623-1. Epub 2018 May 2.

PMID:
29721634
11.

The nomenclature of the basic disease elements of gout: A content analysis of contemporary medical journals.

Bursill D, Taylor WJ, Terkeltaub R, Dalbeth N.

Semin Arthritis Rheum. 2018 Mar 28. pii: S0049-0172(17)30750-3. doi: 10.1016/j.semarthrit.2018.03.017. [Epub ahead of print]

PMID:
29706241
12.

Predictors of activity limitation in people with gout: a prospective study.

Stewart S, Rome K, Eason A, House ME, Horne A, Doyle AJ, Knight J, Taylor WJ, Dalbeth N.

Clin Rheumatol. 2018 Aug;37(8):2213-2219. doi: 10.1007/s10067-018-4110-6. Epub 2018 Apr 21.

PMID:
29680870
13.

Region-specific foot pain and plantar pressure in people with rheumatoid arthritis: A cross-sectional study.

Stewart S, Carroll M, Brenton-Rule A, Keys M, Bell L, Dalbeth N, Rome K.

Clin Biomech (Bristol, Avon). 2018 Jun;55:14-17. doi: 10.1016/j.clinbiomech.2018.04.002. Epub 2018 Apr 4.

PMID:
29631228
14.

Blocking fatty acid-fueled mROS production within macrophages alleviates acute gouty inflammation.

Hall CJ, Sanderson LE, Lawrence LM, Pool B, van der Kroef M, Ashimbayeva E, Britto D, Harper JL, Lieschke GJ, Astin JW, Crosier KE, Dalbeth N, Crosier PS.

J Clin Invest. 2018 May 1;128(5):1752-1771. doi: 10.1172/JCI94584. Epub 2018 Mar 26.

15.

Serum urate as surrogate endpoint for flares in people with gout: A systematic review and meta-regression analysis.

Stamp L, Morillon MB, Taylor WJ, Dalbeth N, Singh JA, Lassere M, Christensen R.

Semin Arthritis Rheum. 2018 Feb 21. pii: S0049-0172(17)30629-7. doi: 10.1016/j.semarthrit.2018.02.009. [Epub ahead of print]

PMID:
29566967
16.

Response to: 'The reference levels of serum urate for clinically evident incident gout' by Chen and Ding.

Dalbeth N, Phipps-Green A, Frampton C, Neogi T, Taylor WJ, Merriman TR.

Ann Rheum Dis. 2018 Mar 21. pii: annrheumdis-2018-213372. doi: 10.1136/annrheumdis-2018-213372. [Epub ahead of print] No abstract available.

PMID:
29563107
17.

What Is the Evidence for Treat-to-Target Serum Urate in Gout?

Bursill D, Dalbeth N.

Curr Rheumatol Rep. 2018 Mar 8;20(3):11. doi: 10.1007/s11926-018-0719-3. Review.

PMID:
29516287
18.

Re: "Widespread prevalence of a CREBRF variant among Māori and Pacific children is associated with weight and height in early childhood".

Major TJ, Krishnan M, Topless RK, Dewes O, Thompson J, Zoysa J, Stamp LK, Dalbeth N, Deka R, Weeks DE, Minster RL, Wilcox P, Grattan D, Shepherd PR, Shelling AN, Murphy R, Merriman TR.

Int J Obes (Lond). 2018 Mar 6. doi: 10.1038/s41366-018-0025-1. [Epub ahead of print] No abstract available.

PMID:
29511321
19.

Relationship between serum urate concentration and clinically evident incident gout: an individual participant data analysis.

Dalbeth N, Phipps-Green A, Frampton C, Neogi T, Taylor WJ, Merriman TR.

Ann Rheum Dis. 2018 Jul;77(7):1048-1052. doi: 10.1136/annrheumdis-2017-212288. Epub 2018 Feb 20.

PMID:
29463518
20.

The Cost-effectiveness of Biannual Serum Urate (SU) Monitoring after Reaching Target in Gout: A Health Economic Analysis Comparing SU Monitoring.

Robinson PC, Dalbeth N, Donovan P.

J Rheumatol. 2018 May;45(5):697-704. doi: 10.3899/jrheum.170199. Epub 2018 Feb 15.

PMID:
29449500
21.

An association of smoking with serum urate and gout: A health paradox.

Fanning N, Merriman TR, Dalbeth N, Stamp LK.

Semin Arthritis Rheum. 2018 Jun;47(6):825-842. doi: 10.1016/j.semarthrit.2017.11.004. Epub 2017 Nov 22. Review.

PMID:
29398126
22.

Association between ABCG2 rs2231142 and poor response to allopurinol: replication and meta-analysis.

Wallace MC, Roberts RL, Nanavati P, Miner JN, Dalbeth N, Topless R, Merriman TR, Stamp LK.

Rheumatology (Oxford). 2018 Apr 1;57(4):656-660. doi: 10.1093/rheumatology/kex467. Review.

PMID:
29342288
23.

The impact of diuretic use and ABCG2 genotype on the predictive performance of a published allopurinol dosing tool.

Wright DFB, Dalbeth N, Phipps-Green AJ, Merriman TR, Barclay ML, Drake J, Tan P, Horne A, Stamp LK.

Br J Clin Pharmacol. 2018 May;84(5):937-943. doi: 10.1111/bcp.13516. Epub 2018 Feb 20.

PMID:
29341237
24.

Imaging tools to measure treatment response in gout.

Dalbeth N, Doyle AJ.

Rheumatology (Oxford). 2018 Jan 1;57(suppl_1):i27-i34. doi: 10.1093/rheumatology/kex445. Review.

PMID:
29272513
25.

The effect of kidney function on the urate lowering effect and safety of increasing allopurinol above doses based on creatinine clearance: a post hoc analysis of a randomized controlled trial.

Stamp LK, Chapman PT, Barclay M, Horne A, Frampton C, Tan P, Drake J, Dalbeth N.

Arthritis Res Ther. 2017 Dec 21;19(1):283. doi: 10.1186/s13075-017-1491-x.

26.

Variability in the Reporting of Serum Urate and Flares in Gout Clinical Trials: Need for Minimum Reporting Requirements.

Stamp LK, Morillon MB, Taylor WJ, Dalbeth N, Singh JA, Lassere M, Christensen R.

J Rheumatol. 2018 Mar;45(3):419-424. doi: 10.3899/jrheum.170911. Epub 2017 Dec 15.

PMID:
29247147
27.

Mitochondrial genetic variation and gout in Māori and Pacific people living in Aotearoa New Zealand.

Gosling AL, Boocock J, Dalbeth N, Harré Hindmarsh J, Stamp LK, Stahl EA, Choi HK, Matisoo-Smith EA, Merriman TR.

Ann Rheum Dis. 2018 Apr;77(4):571-578. doi: 10.1136/annrheumdis-2017-212416. Epub 2017 Dec 15.

PMID:
29247128
28.

Footwear interventions for foot pain, function, impairment and disability for people with foot and ankle arthritis: A literature review.

Frecklington M, Dalbeth N, McNair P, Gow P, Williams A, Carroll M, Rome K.

Semin Arthritis Rheum. 2018 Jun;47(6):814-824. doi: 10.1016/j.semarthrit.2017.10.017. Epub 2017 Nov 3. Review.

29.

"What say ye gout experts?" a content analysis of questions about gout posted on the social news website Reddit.

Derksen C, Serlachius A, Petrie KJ, Dalbeth N.

BMC Musculoskelet Disord. 2017 Nov 23;18(1):488. doi: 10.1186/s12891-017-1856-y.

30.

Brief Report: Validation of a Definition of Flare in Patients With Established Gout.

Gaffo AL, Dalbeth N, Saag KG, Singh JA, Rahn EJ, Mudano AS, Chen YH, Lin CT, Bourke S, Louthrenoo W, Vazquez-Mellado J, Hernández-Llinas H, Neogi T, Vargas-Santos AB, da Rocha Castelar-Pinheiro G, Amorim RBC, Uhlig T, Hammer HB, Eliseev M, Perez-Ruiz F, Cavagna L, McCarthy GM, Stamp LK, Gerritsen M, Fana V, Sivera F, Taylor W.

Arthritis Rheumatol. 2018 Mar;70(3):462-467. doi: 10.1002/art.40381. Epub 2018 Feb 6.

PMID:
29161469
31.

Presence of monosodium urate crystal deposition by dual-energy CT in patients with gout treated with allopurinol.

Dalbeth N, Nicolaou S, Baumgartner S, Hu J, Fung M, Choi HK.

Ann Rheum Dis. 2018 Mar;77(3):364-370. doi: 10.1136/annrheumdis-2017-212046. Epub 2017 Nov 16.

32.

Lesinurad for the treatment of hyperuricaemia in people with gout.

Robinson PC, Dalbeth N.

Expert Opin Pharmacother. 2017 Dec;18(17):1875-1881. doi: 10.1080/14656566.2017.1401609. Epub 2017 Nov 13.

PMID:
29103339
33.

Changes in clinical disease activity are weakly linked to changes in MRI inflammation on treat-to-target escalation of therapy in rheumatoid arthritis.

McQueen FM, Chapman P, Pollock T, D'Souza D, Lee AC, Dalbeth N, Stamp L, Lindsay K, Doyle A.

Arthritis Res Ther. 2017 Oct 24;19(1):241. doi: 10.1186/s13075-017-1433-7.

34.

Analysis of data collected from right and left limbs: Accounting for dependence and improving statistical efficiency in musculoskeletal research.

Stewart S, Pearson J, Rome K, Dalbeth N, Vandal AC.

Gait Posture. 2018 Jan;59:182-187. doi: 10.1016/j.gaitpost.2017.10.018. Epub 2017 Oct 16.

PMID:
29054045
35.

Lesinurad monotherapy in gout patients intolerant to a xanthine oxidase inhibitor: a 6 month phase 3 clinical trial and extension study.

Tausche AK, Alten R, Dalbeth N, Kopicko J, Fung M, Adler S, Bhakta N, Storgard C, Baumgartner S, Saag K.

Rheumatology (Oxford). 2017 Dec 1;56(12):2170-2178. doi: 10.1093/rheumatology/kex350.

PMID:
29029210
36.

Lack of Evidence that Soluble Urate Directly Influences Bone Remodelling: A Laboratory and Clinical Study.

Dalbeth N, Pool B, Chhana A, Lin JM, Tay ML, Tan P, Callon KE, Naot D, Horne A, Drake J, Gamble GD, Reid IR, Grey A, Stamp LK, Cornish J.

Calcif Tissue Int. 2018 Jan;102(1):73-84. doi: 10.1007/s00223-017-0328-6. Epub 2017 Oct 10.

PMID:
29018897
37.

Effects of Febuxostat in Early Gout: A Randomized, Double-Blind, Placebo-Controlled Study.

Dalbeth N, Saag KG, Palmer WE, Choi HK, Hunt B, MacDonald PA, Thienel U, Gunawardhana L.

Arthritis Rheumatol. 2017 Dec;69(12):2386-2395. doi: 10.1002/art.40233.

38.

Influence of genetic variants on renal uric acid handling in response to frusemide: an acute intervention study.

Dalbeth N, Allan J, Gamble GD, Phipps-Green A, Flynn TJ, Mihov B, Horne A, Doughty R, Stamp LK, Merriman TR.

RMD Open. 2017 Apr 11;3(1):e000424. doi: 10.1136/rmdopen-2016-000424. eCollection 2017.

39.

Reporting of conflicts of interest in oral presentations at medical conferences: a delegate-based prospective observational study.

Grey A, Avenell A, Dalbeth N, Stewart F, Bolland MJ.

BMJ Open. 2017 Sep 21;7(9):e017019. doi: 10.1136/bmjopen-2017-017019.

40.

An illness by any other name: The effect of renaming gout on illness and treatment perceptions.

Petrie KJ, MacKrill K, Derksen C, Dalbeth N.

Health Psychol. 2018 Jan;37(1):37-41. doi: 10.1037/hea0000548. Epub 2017 Aug 24.

PMID:
28836797
41.

Allopurinol dose escalation to achieve serum urate below 6 mg/dL: an open-label extension study.

Stamp LK, Chapman PT, Barclay M, Horne A, Frampton C, Tan P, Drake J, Dalbeth N.

Ann Rheum Dis. 2017 Dec;76(12):2065-2070. doi: 10.1136/annrheumdis-2017-211873. Epub 2017 Aug 22.

PMID:
28830881
42.

Discordant American College of Physicians and international rheumatology guidelines for gout management: consensus statement of the Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN).

Dalbeth N, Bardin T, Doherty M, Lioté F, Richette P, Saag KG, So AK, Stamp LK, Choi HK, Terkeltaub R.

Nat Rev Rheumatol. 2017 Sep;13(9):561-568. doi: 10.1038/nrrheum.2017.126. Epub 2017 Aug 10. Review.

PMID:
28794514
43.

Performance of gout definitions for genetic epidemiological studies: analysis of UK Biobank.

Cadzow M, Merriman TR, Dalbeth N.

Arthritis Res Ther. 2017 Aug 9;19(1):181. doi: 10.1186/s13075-017-1390-1.

44.

Categorisation of foot complaints in systemic lupus erythematosus (SLE) from a New Zealand cohort.

Otter SJ, Rohan M, Davies KA, Kumar S, Gow P, Dalbeth N, Corkill M, Panthakalam S, Rome K.

J Foot Ankle Res. 2017 Jul 26;10:33. doi: 10.1186/s13047-017-0217-2. eCollection 2017.

45.

Ultrasound Characteristics of the Achilles Tendon in Tophaceous Gout: A Comparison with Age- and Sex-matched Controls.

Carroll M, Dalbeth N, Allen B, Stewart S, House T, Boocock M, Frampton C, Rome K.

J Rheumatol. 2017 Oct;44(10):1487-1492. doi: 10.3899/jrheum.170203. Epub 2017 Aug 1.

PMID:
28765249
46.

The patient experience of musculoskeletal imaging tests for investigation of inflammatory arthritis: a mixed-methods study.

Bourke S, Taylor WJ, Doyle AJ, Gott M, Dalbeth N.

Clin Rheumatol. 2018 Aug;37(8):2261-2268. doi: 10.1007/s10067-017-3760-0. Epub 2017 Jul 20.

PMID:
28730270
47.

Interaction of the GCKR and A1CF loci with alcohol consumption to influence the risk of gout.

Rasheed H, Stamp LK, Dalbeth N, Merriman TR.

Arthritis Res Ther. 2017 Jul 5;19(1):161. doi: 10.1186/s13075-017-1369-y.

48.

Clinically-evident tophi are associated with reduced muscle force in the foot and ankle in people with gout: a cross-sectional study.

Stewart S, Dalbeth N, Otter S, Gow P, Kumar S, Rome K.

J Foot Ankle Res. 2017 Jun 19;10:25. doi: 10.1186/s13047-017-0207-4. eCollection 2017.

49.

Lesinurad, a Selective Uric Acid Reabsorption Inhibitor, in Combination With Febuxostat in Patients With Tophaceous Gout: Findings of a Phase III Clinical Trial.

Dalbeth N, Jones G, Terkeltaub R, Khanna D, Kopicko J, Bhakta N, Adler S, Fung M, Storgard C, Baumgartner S, Perez-Ruiz F.

Arthritis Rheumatol. 2017 Sep;69(9):1903-1913. doi: 10.1002/art.40159. Epub 2017 Aug 4.

50.

The genetics of gout: towards personalised medicine?

Dalbeth N, Stamp LK, Merriman TR.

BMC Med. 2017 May 31;15(1):108. doi: 10.1186/s12916-017-0878-5. Review.

Supplemental Content

Loading ...
Support Center